Exploring the Molecular Landscape of Lymphocyte Activation Gene-3: A Literature Review

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Sep 27

PMID 39331884

Authors

Jiaqi Nie

Xue Qin

Xiang Tao

Jin Huang

Affiliations

Soon will be listed here.

Abstract

Molecular structure and cellular distribution of lymphocyte activation gene-3 (LAG-3) have been studied extensively since 1990. However, several unresolved questions remain. It is well-established that LAG-3 plays a significant role in maintaining immune homeostasis. The presence of deficiencies in LAG-3 has been observed to be linked with autoimmune disorders, whereas the excessive expression of LAG-3 within the tumor microenvironment hinders immune responses, particularly those mediated by lymphocytes, thereby facilitating immune evasion. Consequently, investigations into these 2 aspects have become a prominent focus in both fundamental and clinical research. The objective of this review is to examine the functions and molecular characteristics of LAG-3, as well as its current clinical applications in the context of tumor immune escape and autoimmune disease. The ultimate aim is to explore and propose novel immune therapy approach.

References

Yang Z, Kim H, Villasboas J, Chen Y, Price-Troska T, Jalali S . Expression of LAG-3 defines exhaustion of intratumoral PD-1 T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017; 8(37):61425-61439. PMC: 5617435. DOI: 10.18632/oncotarget.18251. View

Hu S, Liu X, Li T, Li Z, Hu F . LAG3 (CD223) and autoimmunity: Emerging evidence. J Autoimmun. 2020; 112:102504. DOI: 10.1016/j.jaut.2020.102504. View

Maeda T, Sugiura D, Okazaki I, Maruhashi T, Okazaki T . Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation. J Biol Chem. 2019; 294(15):6017-6026. PMC: 6463702. DOI: 10.1074/jbc.RA119.007455. View

Koyama S, Akbay E, Li Y, Herter-Sprie G, Buczkowski K, Richards W . Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016; 7:10501. PMC: 4757784. DOI: 10.1038/ncomms10501. View

Tawbi H, Schadendorf D, Lipson E, Ascierto P, Matamala L, Castillo Gutierrez E . Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1):24-34. PMC: 9844513. DOI: 10.1056/NEJMoa2109970. View

Oh S, Rankin A, Caton A . CD4+CD25+ regulatory T cells in autoimmune arthritis. Immunol Rev. 2010; 233(1):97-111. PMC: 2908310. DOI: 10.1111/j.0105-2896.2009.00848.x. View

Eurich K, De La Cruz P, Laguna A, Woodman M, McAdams J, Lips E . Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer. Gynecol Oncol. 2023; 174:200-207. DOI: 10.1016/j.ygyno.2023.05.015. View

Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, Maigret B . Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A. 1997; 94(11):5744-9. PMC: 20850. DOI: 10.1073/pnas.94.11.5744. View

Li M, Feng Y, Fang S . Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 2017; 50(4):e5356. PMC: 5423742. DOI: 10.1590/1414-431X20165356. View

10.

Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P . Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. J Immunother Cancer. 2020; 8(2). PMC: 7682474. DOI: 10.1136/jitc-2020-001681. View

11.

Botticelli A, Zizzari I, Scagnoli S, Pomati G, Strigari L, Cirillo A . The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. J Pers Med. 2021; 11(7). PMC: 8304359. DOI: 10.3390/jpm11070651. View

12.

Chihara N, Madi A, Kondo T, Zhang H, Acharya N, Singer M . Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018; 558(7710):454-459. PMC: 6130914. DOI: 10.1038/s41586-018-0206-z. View

13.

Garcia Cruz D, Giri R, Turro D, Balsbaugh J, Adler A, Rodriguez A . Lymphocyte Activation Gene-3 Regulates Dendritic Cell Metabolic Programing and T Cell Priming Function. J Immunol. 2021; 207(9):2374-2384. PMC: 8525871. DOI: 10.4049/jimmunol.2001188. View

14.

Do J, Visperas A, Sanogo Y, Bechtel J, Dvorina N, Kim S . An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. Mucosal Immunol. 2015; 9(1):137-45. PMC: 4662649. DOI: 10.1038/mi.2015.45. View

15.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

16.

Guo M, Qi F, Rao Q, Sun J, Du X, Qi Z . Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Front Immunol. 2021; 12:754961. PMC: 8530014. DOI: 10.3389/fimmu.2021.754961. View

17.

Andrews L, Somasundaram A, Moskovitz J, Szymczak-Workman A, Liu C, Cillo A . Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020; 5(49). PMC: 7901539. DOI: 10.1126/sciimmunol.abc2728. View

18.

Maruhashi T, Sugiura D, Okazaki I, Shimizu K, Maeda T, Ikubo J . Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 2022; 55(5):912-924.e8. DOI: 10.1016/j.immuni.2022.03.013. View

19.

Bae J, Lee S, Park C, Lee Y, Chun T . Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling. J Immunol. 2014; 193(6):3101-12. DOI: 10.4049/jimmunol.1401025. View

20.

Datar I, Sanmamed M, Wang J, Henick B, Choi J, Badri T . Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clin Cancer Res. 2019; 25(15):4663-4673. PMC: 7444693. DOI: 10.1158/1078-0432.CCR-18-4142. View